ReviewExploration of targeted anti-tumor therapy2021
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.
Review in Exploration of targeted anti-tumor therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Bispecific Antibodies in Breast Cancer Immunotherapy: Mechanisms, Advances, and Translational Challenges.Targeted oncology · 2026Review
- HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies.Breast cancer (Dove Medical Press) · 2026Review
- The HER2 target for designing novel multi-peptide vaccine against breast cancer using immunoinformatics and molecular dynamic simulation.Biochemistry and biophysics reports · 2025Article
- Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer.Scientific reports · 2025Article
- Exploring Zanidatamab's efficacy across HER2-positive Malignancies: a narrative review.BMC cancer · 2025Review
- Enhancing HER2 testing in breast cancer: predicting fluorescence in situ hybridization (FISH) scores from immunohistochemistry images via deep learning.The journal of pathology. Clinical research · 2025Article
- Article
- Updates in Treatment of HER2-positive Metastatic Breast Cancer.Current treatment options in oncology · 2024Review
- Loss of chromosome cytoband 13q14.2 orchestrates breast cancer pathogenesis and drug response.Breast cancer research : BCR · 2024Article
- Personalized treatment approach for HER2-positive metastatic breast cancer.Medical oncology (Northwood, London, England) · 2024Review
- HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future.Frontiers in pharmacology · 2024Review
- Polypharmacology: promises and new drugs in 2022.Pharmacological reports : PR · 2023Review
- Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue.Frontiers in oncology · 2022Review
- Prognostic Significance of Low HER2 Expression in Patients With Early Hormone Receptor Positive Breast Cancer.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About 15-20% of all breast cancers (BCs) are defined human epidermal growth factor receptor 2 (HER2)-positive, based on the overexpression of HER2 protein and/or amplification of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.